Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
1.500
+0.050 (3.45%)
At close: Apr 24, 2026, 4:00 PM EDT
1.500
0.00 (-0.01%)
After-hours: Apr 24, 2026, 6:07 PM EDT
Company Description
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits.
The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients.
it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name.
The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Cibus, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Peter Beetham |
Contact Details
Address: 6455 Nancy Ridge Drive San Diego, California 92121 United States | |
| Phone | 858 450 0008 |
| Website | cibus.com |
Stock Details
| Ticker Symbol | CBUS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001705843 |
| CUSIP Number | 17166A101 |
| ISIN Number | US17166A1016 |
| Employer ID | 27-1967997 |
| SIC Code | 2870 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter R. Beetham B.Sc., Ph.D. | Co-Founder, Interim Chief Executive Officer, President, Chief Operating Officer and Director |
| Rory Balfour Riggs M.B.A. | Co-Founder and Director |
| Cornelis Broos M.Sc. | Chief Financial Officer |
| Dr. Gregory F. Gocal Ph.D. | Co-Founder, Chief Scientific Officer and Executive Vice President |
| Jason Stokes Esq., J.D. | Chief Administrative Officer, General Counsel and Corporate Secretary |
| Rosa Cheuk Kim J.D. | Senior Vice President of Legal |
| Dr. Noel Sauer Ph.D. | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | ARS | Filing |
| Apr 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 20, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 424B5 | Filing |
| Mar 25, 2026 | 424B5 | Filing |
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |